Anti-Fibrinolytic Drugs - Lebanon

The Anti-Fibrinolytic Drugs market in Lebanon is anticipated to witness a significant increase in revenue, with projections indicating that it will reach US$4.23m by the year 2024.
Moreover, it is expected that the market will experience an annual growth rate of 3.51% from 2024 to 2029, resulting in a market volume of US$5.03m by the end of the forecast period.
In a global context, United States is expected to generate the highest revenue in the Anti-Fibrinolytic Drugs market, projected to reach an impressive US$9.86bn in 2024.
Lebanon is experiencing an increasing demand for anti-fibrinolytic drugs, driven by a growing aging population and rising cases of cardiovascular diseases.

Definition:
The Anti-Fibrinolytics market covers drugs which help blood to clot. They are used to treat and prevent bleeding episodes of patients with hemophilia. Moreover, anti-fibrinolytics are used before or during certain surgeries. In doing so, the usage of blood products, such as fresh frozen plasma, as well as the associated risks of infections and/or anaphylactic reactions can be avoided.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Roche, Takeda, Novo Nordisc, Sanofi, Bayer

Inhibitors of fibrinolysis
Drugs to treat hemophilia

Anti-coagulants
Anti-hypertensives
Wound care

The Anti-Fibrinolytic Drugs market in Lebanon is experiencing some interesting trends and developments that are worth exploring.

Customer preferences: Lebanese customers are becoming more aware of the importance of preventing excessive bleeding in surgical procedures. As a result, there is a growing demand for Anti-Fibrinolytic Drugs that can help control bleeding and reduce the need for blood transfusions. Additionally, there is a preference for drugs that are easy to administer and have minimal side effects.

Trends in the market: The Anti-Fibrinolytic Drugs market in Lebanon is expected to grow steadily in the coming years due to an increase in the number of surgical procedures being performed. This growth is also being driven by the introduction of new and innovative drugs that are more effective and have fewer side effects than traditional treatments. Furthermore, there is a trend towards the use of combination therapies, where Anti-Fibrinolytic Drugs are used in conjunction with other medications to achieve better outcomes.

Local special circumstances: Lebanon has a well-developed healthcare system, which is accessible to a large portion of the population. However, the country has been facing economic and political challenges in recent years, which have led to a decrease in government spending on healthcare. This has resulted in a higher out-of-pocket cost for patients, which may impact their ability to access and afford Anti-Fibrinolytic Drugs.

Underlying macroeconomic factors: Lebanon's economy has been struggling in recent years due to political instability and a high level of public debt. This has led to a decrease in foreign investment and a decline in economic growth. Additionally, the COVID-19 pandemic has had a significant impact on the country's economy, leading to a decrease in consumer spending and a slowdown in economic activity. These macroeconomic factors may impact the growth of the Anti-Fibrinolytic Drugs market in Lebanon in the short term.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Bleeding disorders affect the clotting of blood and can result in excessive bleeding inside and outside of the body. Bleeding disorders are almost always inherited and common symptoms include easy bruising, frequent nosebleeds, heavy menstrual bleeding, and excessive bleeding from small cuts. Treatments vary depending on the type of disorder, but may include factor replacement therapy, iron supplementation, topical products or sprays, or blood transfusions. The most common types of bleeding disorders are hemophilia A and B and von Willebrand disease. In 2022, there were around 257,146 people worldwide who had been diagnosed with hemophilia and 100,505 who had been diagnosed with von Willebrand disease.